advanced or metastatic cancers (multi-indication)
Oncology · 2025–2025
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Advanced and metastatic cancers across multiple indications including melanoma, NSCLC, urothelial carcinoma, classical Hodgkin lymphoma, endometrial carcinoma,… | Jul 2025 | Not recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.